IL-12 protects from psoriasiform skin inflammation

P Kulig, S Musiol, S N Freiberger, B Schreiner, G Gyülveszi, G Russo, S Pantelyushin, K Kishihara, F Alessandrini, T Kündig, F Sallusto, G F L Hofbauer (+2 others)
Neutralization of the common p40-subunit of IL-12/23 in psoriasis patients has led to a breakthrough in the management of moderate to severe disease. Aside from neutralizing IL-23, which is thought to be responsible for the curative effect, anti-p40 therapy also interferes with IL-12 signalling and type 1 immunity. Here we dissect the individual contribution of these two cytokines to the formation of psoriatic lesions and understand the effect of therapeutic co-targeting of IL-12 and IL-23 in
more » ... oriasis. Using a preclinical model for psoriatic plaque formation we show that IL-12, in contrast to IL-23, has a regulatory function by restraining the invasion of an IL-17-committed gdT (gdT17) cell subset. We discover that IL-12 receptor signalling in keratinocytes initiates a protective transcriptional programme that limits skin inflammation, suggesting that collateral targeting of IL-12 by anti-p40 monoclonal antibodies is counterproductive in the therapy of psoriasis. | 1% penicillin (Gibco), 1% streptomycin (Gibco), 1% amphotericin B (Gibco) and 10 mg ml À 1 dispase (Roche). Afterwards, the epidermis was separated manually and incubated in pre-warmed 0.25% trypsin-EDTA (Gibco) for B5 min. Keratinocytes were scratched off the epidermis and centrifuged at 1,500 r.p.m. for NATURE COMMUNICATIONS |
doi:10.5167/uzh-128503 fatcat:d6e5exnh2zaofd5c4vu5uqd7b4